Data from 54,000 patients in Japan reveals a precision oncology bottleneck. While 72.7% of tumors harbored actionable alterations, only ~8% received matched therapy. Future progress demands integrating multi-omics and AI.
#MedSky 🧬💻
#MLSky
Going beyond genomics in precision oncology - Nature Medicine
A large population-based study from Japan reveals both the promise and the limits of genomic profiling in cancer care, and highlights the need for multidimensional data to guide therapy across…
